ӳ��ý

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.

Kim KH, Kim W, Howard TP, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21(12):1491-6. doi:10.1038/nm.3968

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.

Gusev A, Shi H, Kichaev G, et al. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016;7:10979. doi:10.1038/ncomms10979

SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b.

Kugel S, Sebastián C, Fitamant J, et al. SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell. 2016;165(6):1401-15. doi:10.1016/j.cell.2016.04.033

Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.

Wagner FF, Weïwer M, Steinbacher S, et al. Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors. Bioorg Med Chem. 2016;24(18):4008-4015. doi:10.1016/j.bmc.2016.06.040

Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.

Ryan RJH, Drier Y, Whitton H, et al. Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. Cancer Discov. 2015;5(10):1058-71. doi:10.1158/2159-8290.CD-15-0370

Small-molecule reagents for cellular pull-down experiments.

Wang X, Imber BS, Schreiber SL. Small-molecule reagents for cellular pull-down experiments. Bioconjug Chem. 2008;19(3):585-7. doi:10.1021/bc700297j